Actively Recruiting
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Led by Chang Gung Memorial Hospital · Updated on 2026-03-19
80
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.
CONDITIONS
Official Title
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
- MMSE score between 10 and 26
- Clinical Dementia Rating (CDR) of 1 or 0.5
You will not qualify if you...
- Hachinski Ischemic Score greater than 4
- History of substance abuse or dependence
- Presence of Parkinson disease, epilepsy, or dementia with psychotic features
- Diagnosis of major depressive disorder
- Major physical illnesses
- Severe visual or hearing impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chang Gung Memorial Hospital
Kaohsiung City, Taiwan, 886
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here